cretostimogene grenadenorepvec

AXP000006.2 · Oncolytic virus

Platform
adenovirus (Ad5, E2F-1 promoter-driven E1A, E3-deleted)
Originator
Cell Genesys
Sponsor
CG Oncology

Names

NameTypeSource
cretostimogene grenadenorepvecpreferred name, INNcurator, ncit
cretostimogeneINNctgov
CG0070codencit
Oncolytic Adenovirus Encoding GM-CSF ambiguoussynonymncit

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5 (CG0070)
Replication
conditionally replicating
Modifications
E2F-1 promoter drives E1A; E3 region deleted
Transgenes
CSF2
Route
intravesical
Source
evidence

Cross-references

NCI Thesaurus
C48412
FDA UNII
THP9ML4NTZ

Approvals

No regulatory approval recorded.

Clinical trials (12)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07283835Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-GuerinRecruitingPhase 22025-12-042027-12-3116High-grade Ta/ T1 Papillary Disease Bladder Cancer; Non Muscle Invasive Bladder Cancer
NCT06567743Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBCRecruitingPhase 22024-09-162027-03-31325High-Risk Non-Muscle-Invasive Bladder Cancer
NCT06253845Study of CG0070 After Transurethral Resection in Patients With IR NMIBCActive not recruitingPhase 12024-03-012027-0920Non-muscle Invasive Bladder Cancer
NCT06111235A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTActive not recruitingPhase 32023-12-142026-11367Bladder Cancer; Non Muscle Invasive Bladder Cancer; Urologic Cancer; Urothelial Carcinoma
NCT04387461Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-GuerinCompletedPhase 22020-12-082023-03-0735Non Muscle Invasive Bladder Cancer
NCT04452591Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-GuerinActive not recruitingPhase 32020-10-272030-06-16190High-grade Ta/ T1 Papillary Disease Bladder Cancer; Non Muscle Invasive Bladder Cancer
NCT04610671Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBCCompletedPhase 12020-10-262024-07-2521Bladder Cancer; Muscle-Invasive Bladder Carcinoma
NCT02365818Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG FailureCompletedPhase 22015-06-022018-0866Bladder Cancer
NCT02143804Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder CancerWithdrawnPhase 22014-032015-030Bladder Cancer; High Grade; Non Muscle Invasive
NCT01438112Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder CancerTerminatedPhase 2/32014-032016-0622Bladder Cancer; Carcinoma in Situ; Carcinoma in Situ Concurrent With Papillary Tumors; Transitional Cell Carcinoma
NCT00109655Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) FailureUnknownPhase 12005-042008-1075Bladder Neoplasms; Carcinoma, Transitional Cell
NCT06443944An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCGAvailableBladder Cancer; Non-Muscle Invasive Bladder Cancer; Urologic Cancer; Urothelial Carcinoma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 42508433Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.The Lancet. Oncology2026cited by trial NCT04452591
PMID 39521884Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial.Nature medicine2025cited by trial NCT04610671
PMID 38844794Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.Nature medicine2024cited by trial NCT04387461
PMID 28755959An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.Urologic oncology2018name in title: CG0070
PMID 23088985A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer.The Journal of urology2012name in title: CG0070

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41325798Oncolytic virotherapy: Molecular mechanisms, delivery strategies, and translational insights.Critical reviews in oncology/hematology2026name in abstract: CG0070
PMID 41422765Urothelial Carcinoma In Situ: Advances in Diagnosis and Management.Clinical genitourinary cancer2026name in abstract: CG0070
PMID 41555169[Evolving Pharmacotherapy for Bladder Cancer-From Non-Muscle-Invasive to Metastatic Disease-Development of Novel Therapies for BCG-Unresponsive NMIBC].Gan to kagaku ryoho. Cancer & chemotherapy2026name in abstract: cretostimogene grenadenorepvec
PMID 41647170Current use of pre-clinical models for evaluation of human adenovirus-based cancer therapeutics.Molecular therapy. Oncology2026name in abstract: cretostimogene grenadenorepvec
PMID 41825577Advances in intravesical therapy for non-muscle-invasive bladder cancer.Critical reviews in oncology/hematology2026name in abstract: CG0070
PMID 42216552Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer.Frontiers in bioscience (Landmark edition)2026name in abstract: cretostimogene grenadenorepvec
PMID 42260513Immunotherapy in bladder cancer: a systematic review of clinical trials and therapeutic advances.BMC urology2026name in abstract: cretostimogene grenadenorepvec
PMID 42362299Emerging Intravesical Therapies for Non-Muscle-Invasive Bladder Cancer.The Urologic clinics of North America2026name in abstract: cretostimogene
PMID 42508430Cretostimogene grenadenorepvec: promise beyond response.The Lancet. Oncology2026name in title: cretostimogene grenadenorepvec
PMID 42798234Trial design drives outcomes: harmonising efficacy across BCG-unresponsive bladder carcinoma in situ trials.BJU international2026name in abstract: cretostimogene grenadenorepvec
PMID 42967132Bladder-Sparing Therapies for Bacillus Calmette-Guérin-Unresponsive Carcinoma In Situ: An Upper and a Lower Response Group With an Unstable Boundary.Cureus2026name in abstract: cretostimogene
PMID 39779686Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer.Expert opinion on biological therapy2025name in abstract: cretostimogene grenadenorepvec
PMID 39933135New Treatment Options for Non-Muscle-Invasive Bladder Cancer.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting2025name in abstract: CG0070
PMID 40304944Current State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder Cancer and Localized Muscle Invasive Bladder Cancer.Current oncology reports2025name in abstract: cretostimogene grenadenorepvec
PMID 40584211Emerging bladder-sparing treatments for high risk non-muscle invasive bladder cancer.Bladder cancer (Amsterdam, Netherlands)2025name in abstract: CG0070
PMID 40923119Oncolytic virus therapy for nonmuscle-invasive bladder cancer: current status and future directions.Current opinion in urology2025name in abstract: cretostimogene grenadenorepvec
PMID 40932192[INNOVATIONS IN THERAPIES FOR BACILLUS CALMETTE-GUERIN (BCG) FAILURE NON-MUSCLE INVASIVE PATIENTS].Harefuah2025name in abstract: cretostimogene grenadenorepvec
PMID 40948378Mechanisms, Clinical Trials, and New Treatments for BCG-Unresponsive in Nonmuscle Invasive Bladder Cancer.Cancer medicine2025name in abstract: CG0070
PMID 40970394Gene-mediated therapy for BCG-unresponsive nonmuscle-invasive bladder cancer: mechanisms, clinical evidence, and practical implementation.Current opinion in urology2025name in abstract: cretostimogene
PMID 41300998Gene Therapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: Current Evidence and Future Directions.Cancers2025name in abstract: cretostimogene grenadenorepvec
PMID 41425090Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies.Frontiers in cell and developmental biology2025name in abstract: CG0070
PMID 38886756Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment.Journal of experimental & clinical cancer research : CR2024name in abstract: cretostimogene grenadenorepvec
PMID 36949824A systematic review on the available treatment modalities for Bacillus Calmette-Guérin-unresponsive carcinoma in situ and tumors in patients who are ineligible for or decline radical cystectomy.SAGE open medicine2023name in abstract: CG0070
PMID 37410243Intravesical Infusion of Oncolytic Virus CG0070 in the Treatment of Bladder Cancer.Methods in molecular biology (Clifton, N.J.)2023name in title: CG0070
PMID 35158964From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC).Cancers2022name in abstract: CG0070
PMID 36051251Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments.Archives of pharmacology and therapeutics2022name in abstract: CG0070
PMID 30462296Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.Japanese journal of clinical oncology2019name in abstract: CG0070
PMID 27486853Oncolytic virus therapy: A new era of cancer treatment at dawn.Cancer science2016name in abstract: CG0070
PMID 20629483Use of a bioamplification assay to detect nonselective recombinants and assess the genetic stability of oncolytic adenoviruses.Human gene therapy2010name in abstract: CG0070
PMID 16397056CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer.Clinical cancer research : an official journal of the American Association for Cancer Research2006name in title: CG0070
PMID 17003851Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2006name in abstract: CG0070

Notes

Cell Genesys -> BioSante (2009 merger) -> Cold Genesys (acquired asset 2010); Cold Genesys renamed CG Oncology in March 2020. Kissei holds Japan/Asia rights (2020). Transgenes moved from targets to virus.tsv (spec 0.2).

How to cite

cretostimogene grenadenorepvec (AXP000006.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000006.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.